Gastric cancer is the second most common cause of cancer death worldwide. Recent development of targeted agents provides clinicians with additional systemic treatment options to conventional cytotoxic agents. Predictive markers are undoubtedly important for guiding the appropriate use of targeted and cytotoxic agents. Currently, however, HER2 is the only predictive biomarker validated for gastric cancer. In this review, candidate predictive markers for response to other targeted agents and cytotoxic chemotherapeutic agents are discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670597 | PMC |
| http://dx.doi.org/10.2217/pgs.13.250 | DOI Listing |
Publication Analysis
Top Keywords
gastric cancer
12
cytotoxic agents
12
predictive biomarker
8
targeted cytotoxic
8
targeted agents
8
predictive markers
8
agents
6
predictive
4
biomarker candidates
4
candidates response
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!